<DOC>
	<DOCNO>NCT02840123</DOCNO>
	<brief_summary>The purpose study asses safety diffuse intrinsic pontine glioma ( DIPG ) treatment autologous dendritic cell pulse lysated allegenic tumor line Evaluate nonspecific immune response generate peripheral blood Cerebral Spinal Fluid ( CSF ) propose treatment Evaluate specific antitumor immunity response generate peripheral blood CSF Assess overall survival progression free survival Correlate neuroradiological change clinical course immune response generate peripheral blood CSF Quality life evaluation</brief_summary>
	<brief_title>Safety Study DIPG Treatment With Autologous Dendritic Cells Pulsed With Lysated Allegenic Tumor Lines</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<criteria>Newly diagnose DIPG Patients without progressive disease Aged 3 18 yo Lansky scale &gt; 50 ( Karnofsky patient age 16 yr ) Life expectancy &gt; 8 week Preserved bone marrow function Normal hepatic renal function Impossibility perform aphaeresis Patient participation experimental study within last 3 month Patient antitumor treatment last 4 week Comorbidity allow study treatment Patients require &gt; 2mg/day dexamethasone treatment Corticoiddependent patient Patients uncontrolled infection Positive serology HIV , hepatitis C virus ( HCV ) hepatitis B virus ( HBV )</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>